Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma-Reference-Cited by-同舟云学术

Prognostic differences between carmustine, etoposide, cytarabine and melphalan (BEAM) and carmustine, etoposide, cytarabine, melphalan and fludarabine (BEAMF) regimens before autologous stem cell transplantation plus chimeric antigen receptor T therapy in patients with refractory/relapsed B-cell non-Hodgkin-lymphoma

Published:2024-05 Issue:5 Volume:26 Page:456-465
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Xin Xiangke^ORCID,Lin Li,Yang Yang,Wang Na,Wang Jue,Xu Jinhuan,Wei Jia,Huang Liang,Zheng Miao^ORCID,Xiao Yi,Meng Fankai,Cao Yang,Zhu Xiaojian,Zhang Yicheng

Funder

National Natural Science Foundation of China

National High-tech Research and Development Program

Publisher

Elsevier BV

Reference59 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;The New England journal of medicine,1995

2. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support;Milpied;The New England journal of medicine,2004

3. Relapsed/refractory diffuse large B-cell lymphoma;Friedberg;Hematology American Society of Hematology Education Program,2011

4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

5. Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the GEL/TAMO experience;Rodriguez;Ann Oncol,2004

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD19 CAR-T treatment shows limited efficacy in r/r DLBCL with double expression and TP53 alterations;Cytotherapy;2024-07

2. Adverse Reactions in Relapsed/Refractory B-Cell Lymphoma Administered with Chimeric Antigen Receptor T Cell Alone or in Combination with Autologous Stem Cell Transplantation;Cancers;2024-04-28